Apixaban for the treatment of saphenous vein graft thrombosi
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Saphenous vein graft (SVG) occlusion with thrombus formation is a substantial cause of acute coronary syndrome, including unstable angina, in patients undergoing coronary artery bypass graft (CABG) surgery. Percutaneous coronary intervention (PCI) is considered to be a first-line option. However, SVG angioplasty is associated with frequent periprocedural complications due to distal embolization. Therefore, the therapeutic approach in unstable angina due to SVG thrombosis is still controversial. Here we describe a case demonstrating that apixaban, a novel oral anticoagulant was effective for unstable angina due to SVG thrombosis and might be an alternative to PCI...

https://thrombosisjournal.biomedcentral.com/articles/10.1186/s12959-017-0133-5
Like
Comment
Share